Scholarlink

<p>Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor symptoms (e.g., tremor, bradykinesia, rigidity, and postural instability) and non-motor complications. This study presents the case of an 83-year-old male Parkinson’s disease patient whose severe motor symptoms—including tremors, bradykinesia, and gait difficulties—persisted despite levodopa treatment. Consequently, THC-rich <i>Cannabis</i> oil was introduced as adjunct therapy. Over 9&#xa0;months, the patient received <i>Cannabis sativa</i> L., Cannabaceae, oils with differing Δ<sup>9</sup>-tetrahydrocannabinol (THC):cannabidiol (CBD) concentrations under a titration protocol to identify the optimal dose. Clinical outcomes were assessed periodically using the Unified Parkinson’s Disease Rating Scale (primary outcome), alongside scales evaluating psychiatric symptoms, quality of life, and cognition. At 8&#xa0;months, a dose of 18.25&#xa0;mg THC/day (divided into three administrations) yielded the patient’s self-reported peak physical well-being and a 54.55% reduction in Unified Parkinson’s Disease Rating Scale scores, indicating significant motor symptom improvement. Secondary benefits included enhanced quality of life and improved sleep, in addition to reduced depressive and anxious symptoms. No significant adverse effects were reported. These findings suggest that high-dose THC may be safe and effective for mitigating motor and non-motor Parkinson’s disease symptoms. Cannabinoids, particularly THC, show therapeutic potential for Parkinson’s disease management, though larger studies are needed to confirm long-term efficacy and safety.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A High-Dose THC Cannabis Oil Improves Motor and Non-motor Symptoms in Parkinson’s Disease: A Case Report

  • 期刊论文

  • 发表日期：

    2025年7月21日

查看全文
  • Luís Eduardo Dall’soto,
  • Karoline Bach Pauli,
  • Yasmin Rafaela Correia Fakih,
  • Jeisson Brandway Blanco Castañeda,
  • Aline Theodoro Toci,
  • Maria Aparecida Felício de Carvalho,
  • Plínio Miguel Loguercio Quinette,
  • Elton Gomes da Silva,
  • Luana Oliveira,
  • Francisney Pinto Nascimento

摘要

Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor symptoms (e.g., tremor, bradykinesia, rigidity, and postural instability) and non-motor complications. This study presents the case of an 83-year-old male Parkinson’s disease patient whose severe motor symptoms—including tremors, bradykinesia, and gait difficulties—persisted despite levodopa treatment. Consequently, THC-rich Cannabis oil was introduced as adjunct therapy. Over 9 months, the patient received Cannabis sativa L., Cannabaceae, oils with differing Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) concentrations under a titration protocol to identify the optimal dose. Clinical outcomes were assessed periodically using the Unified Parkinson’s Disease Rating Scale (primary outcome), alongside scales evaluating psychiatric symptoms, quality of life, and cognition. At 8 months, a dose of 18.25 mg THC/day (divided into three administrations) yielded the patient’s self-reported peak physical well-being and a 54.55% reduction in Unified Parkinson’s Disease Rating Scale scores, indicating significant motor symptom improvement. Secondary benefits included enhanced quality of life and improved sleep, in addition to reduced depressive and anxious symptoms. No significant adverse effects were reported. These findings suggest that high-dose THC may be safe and effective for mitigating motor and non-motor Parkinson’s disease symptoms. Cannabinoids, particularly THC, show therapeutic potential for Parkinson’s disease management, though larger studies are needed to confirm long-term efficacy and safety.

Graphical Abstract